Tarsus Pharmaceuticals, Inc. (TARS) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST
Company Participants
David Nakasone – Head of Investor Relations
Bobak Azamian – Co-Founder, President, CEO & Chairman
Aziz Mottiwala – Chief Commercial Officer
Jeffrey S. Farrow – CFO & Chief Strategy Officer
Seshadri Neervannan – Chief Operating Officer
Conference Call Participants
Andreas Argyrides – Oppenheimer & Co. Inc., Research Division
Eddie Hickman – Guggenheim Securities, LLC, Research Division
Jason Gerberry – BofA Securities, Research Division
Andrea Tan – Goldman Sachs Group, Inc., Research Division
Lachlan Hanbury-Brown – William Blair & Company L.L.C., Research Division
Cory Jubinville – LifeSci Capital, LLC, Research Division
Yuchen Ding – Jefferies LLC, Research Division
Matthew Caufield – H.C. Wainwright & Co, LLC, Research Division
Presentation
Operator
Good afternoon, and welcome to Tarsus’ Third Quarter 2025 Financial Results Conference Call. As a reminder this call is being recorded. [Operator Instructions]
At this time, I would like to turn the call over to David Nakasone, Head of Investor Relations, to lead off the call. David, you may begin.
David Nakasone
Head of Investor Relations
Thank you. Before we begin, I encourage everyone to visit the Investors section of the Tarsus’ website to view the earnings release and related materials we will be discussing today.
Joining me on the call this afternoon are, Bobby Azamian, our Chief Executive Officer and Chairman; Aziz Mottiwala, our Chief Commercial Officer; and Jeff Farrow, our Chief Financial Officer and Chief Strategy Officer.
I’d like to draw your attention to Slide 3, which contains our forward-looking statements. During this call, we will be making forward-looking statements that are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to consult the risk factors contained in our SEC filings for additional detail.
With
